Affinity Asset Advisors, LLC: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1773195) · Explore on the interactive board
Affinity Asset Advisors, LLC disclosed 104 US equity positions worth $2.0bn in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 13, 2026). Its largest position is ROIV at 6.5% of the reported book, followed by APGE, SYRE. The top ten holdings are 42.6% of the book, and the portfolio behaves like about 37 equal-weight positions. Versus the prior filing it opened 19 new positions, added to 33, reduced 28 and exited 10. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Affinity Asset Advisors, LLC own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 19 new, 33 added, 28 reduced, 10 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | ROIV ROIVANT SCIENCES LTD | Healthcare | 6.5% | $132.7m | 3,750,000 | 34% | added |
| 2 | APGE APOGEE THERAPEUTICS INC | Healthcare | 6.4% | $131.0m | 987,000 | -23% | reduced |
| 3 | SYRE SPYRE THERAPEUTICS INC | Healthcare | 5.6% | $113.6m | 1,279,134 | 0% | held |
| 4 | XENE XENON PHARMACEUTICALS INC | Healthcare | 4.7% | $96.3m | 1,595,000 | -5% | reduced |
| 5 | ERAS ERASCA INC | Healthcare | 4.7% | $96.2m | 5,250,000 | -2% | reduced |
| 6 | INSM INSMED INC | Healthcare | 3.4% | $69.3m | 650,000 | 35% | added |
| 7 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 3.0% | $61.9m | 185,000 | 9% | added |
| 8 | ALKS ALKERMES PLC | Healthcare | 2.9% | $58.9m | 1,125,000 | -17% | reduced |
| 9 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 2.7% | $56.2m | 590,000 | 18% | added |
| 10 | ANAB ANAPTYSBIO INC | Healthcare | 2.7% | $55.8m | 826,109 | -12% | reduced |
| 11 | AVTX AVALO THERAPEUTICS INC | Healthcare | 2.6% | $53.6m | 2,900,000 | 116% | added |
| 12 | CYTK CYTOKINETICS INC | Healthcare | 2.3% | $46.9m | 550,000 | -21% | reduced |
| 13 | RVMD REVOLUTION MEDICINES INC | Healthcare | 2.3% | $46.8m | 250,000 | 150% | added |
| 14 | ABVX ABIVAX SA | Healthcare | 2.2% | $44.0m | 330,000 | -19% | reduced |
| 15 | TRAX FIRST TRACKS BIOTHERAPEUTICS | 2.0% | $40.9m | 2,032,012 | – | new | |
| 16 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 1.9% | $39.0m | 400,000 | 14% | added |
| 17 | STRO SUTRO BIOPHARMA INC | Healthcare | 1.9% | $38.9m | 1,172,487 | 10% | added |
| 18 | NUVALENT INC | 1.7% | $34.0m | 275,000 | -8% | reduced | |
| 19 | TRVI TREVI THERAPEUTICS INC | Healthcare | 1.6% | $33.6m | 1,800,172 | -10% | reduced |
| 20 | OVID OVID THERAPEUTICS INC | Healthcare | 1.3% | $27.3m | 10,144,562 | -5% | reduced |
| 21 | LXEO LEXEO THERAPEUTICS INC | Healthcare | 1.3% | $27.0m | 5,807,611 | 15% | added |
| 22 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 1.3% | $26.0m | 700,000 | 40% | added |
| 23 | BLTE BELITE BIO INC | Healthcare | 1.2% | $25.4m | 165,000 | 154% | added |
| 24 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 1.2% | $25.4m | 500,000 | -15% | reduced |
| 25 | FBRX FORTE BIOSCIENCES INC | 1.2% | $24.3m | 1,145,391 | 13% | added | |
| 26 | NRIX NURIX THERAPEUTICS INC | Healthcare | 1.1% | $23.5m | 967,620 | 0% | held |
| 27 | ANRO ALTO NEUROSCIENCE INC | Healthcare | 1.1% | $22.4m | 850,000 | 70% | added |
| 28 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 1.1% | $21.5m | 40,000 | -27% | reduced |
| 29 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 1.0% | $21.1m | 172,125 | 0% | held |
| 30 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 1.0% | $20.2m | 750,000 | 0% | held |
| 31 | RLAY RELAY THERAPEUTICS INC | Healthcare | 1.0% | $19.6m | 1,050,000 | 162% | added |
| 32 | SGMT SAGIMET BIOSCIENCES INC | Healthcare | 0.9% | $19.3m | 2,497,864 | 188% | added |
| 33 | JBIO JADE BIOSCIENCES INC | Healthcare | 0.9% | $18.7m | 840,350 | 31% | added |
| 34 | COGT COGENT BIOSCIENCES INC | Healthcare | 0.9% | $17.4m | 450,000 | -40% | reduced |
| 35 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 0.8% | $17.0m | 300,000 | 0% | held |
| 36 | CGEM CULLINAN THERAPEUTICS INC | Healthcare | 0.8% | $15.9m | 875,760 | 12% | added |
| 37 | SVRA SAVARA INC | Healthcare | 0.8% | $15.5m | 2,512,153 | 0% | held |
| 38 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 0.7% | $14.9m | 400,000 | – | new |
| 39 | CATX PERSPECTIVE THERAPEUTICS INC | 0.7% | $14.4m | 4,214,582 | 33% | added | |
| 40 | ODYSSEY THERAPEUTICS INC | 0.7% | $14.3m | 766,346 | – | new | |
| 41 | COGENT BIOSCIENCES INC | 0.7% | $13.7m | 11,000,000 | 57% | added | |
| 42 | HELIX ACQUISITION CORP III | 0.7% | $13.3m | 1,250,000 | 0% | held | |
| 43 | EQ EQUILLIUM INC | 0.6% | $13.1m | 4,100,000 | 234% | added | |
| 44 | ESTA ESTABLISHMENT LABS HLDGS INC | Healthcare | 0.6% | $12.7m | 148,013 | 48% | added |
| 45 | CLYM CLIMB BIO INC | Healthcare | 0.6% | $12.7m | 972,000 | 39% | added |
| 46 | TEVA TEVA PHARMACEUTICAL INDS LTD | Healthcare | 0.6% | $12.7m | 374,000 | -73% | reduced |
| 47 | MANE VERADERMICS INC | Healthcare | 0.6% | $12.3m | 100,000 | 43% | added |
| 48 | ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 0.6% | $12.2m | 150,000 | -25% | reduced |
| 49 | OMEROS CORP | 0.6% | $12.2m | 6,525,000 | 0% | held | |
| 50 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 0.6% | $11.9m | 1,750,000 | 75% | added |
What did Affinity Asset Advisors, LLC sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| CNTA CENTESSA PHARMACEUTICALS PLC | 30.0% | $55.6m |
| ACLXGBX ARCELLX INC | 22.5% | $41.7m |
| 430 TERNS PHARMACEUTICALS INC | 16.0% | $29.7m |
| ASND ASCENDIS PHARMA A/S | 11.7% | $21.7m |
| BBIO BRIDGEBIO PHARMA INC | 6.0% | $11.1m |
| WVE WAVE LIFE SCIENCES LTD | 5.5% | $10.2m |
| CELCUITY INC | 4.0% | $7.3m |
| ENGENE HOLDINGS INC | 2.2% | $4.2m |
| CORT CORCEPT THERAPEUTICS INC | 1.1% | $2.0m |
| 2KZ0 KEZAR LIFE SCIENCES INC | 0.9% | $1.7m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 84.6% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Affinity Asset Advisors, LLC's portfolio?
Across every quarter Affinity Asset Advisors, LLC has filed, its median largest position is 6.4% of the book and its median top-ten weight is 42.5%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 9.0 completed holding spells, the median lasted 1.0 quarters; 104.0 positions are still open and their final length is unknown.